July 19 | 2021
2cureX receives important ISO 13485:2016 certification
Read more
July 1 | 2021
2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer
Read more
June 22 | 2021
2cureX appoints 2 new VPs for its Commercial Operations
Read more
June 7 | 2021
ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients
Read more
June 4 | 2021
REDEYE releases an updated 2cureX Equity Research Report
Read more
May 27 | 2021
Kommuniké från årsstämma i 2cureX AB
Read more
May 27 | 2021
Communiqué from the Annual General Meeting of 2cureX AB
Read more
May 20 | 2021
2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting
Read more
May 6 | 2021
Mangold Fondkommission AB published an Analyst Report on 2cureX
Read more
April 27 | 2021
2cureX’s CEO Fernando Andreu is buying shares in the company
Read more
April 26 | 2021
2cureX styrelse och ledning nyttjar samtliga innehavda teckningsoptioner av serie TO1 för 6,04 MSEK
Read more
April 26 | 2021
Board and management of 2cureX exercise all held warrants of series TO1 for SEK 6.04 million
Read more
April 24 | 2021
Correction of “Notice to attend the Annual General Meeting of 2cureX AB” issued on 23[rd] April 2021.
Read more
April 24 | 2021
Korrektion till ”Kallelse till årsstämma i 2cureX AB” utfärdad den 23 april 2021.
Read more
April 23 | 2021
Notice to attend the Annual General Meeting of 2cureX AB
Read more
April 23 | 2021
Kallelse till årsstämma i 2cureX AB
Read more
March 2 | 2021
2cureX Clinical Newsletter
Read more